Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAD and ASCT in Newly Diagnosed Multiple Myeloma
NCT01852799Phase 2Completed
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Dec 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Shanghai Changzheng Hospital. Started Dec 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01852799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01852799.